EYEN Eyenovia Inc

Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

Company to host an investor conference call and webcast at 4:30pm EDT

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the Company will release financial results for the second quarter ended June 30, 2023 on Thursday, August 10, 2023, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. EDT to review the financial and operating results.

Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and referencing conference ID 13739696.

To access the Call me™ feature, which avoids having to wait for an operator, click .

A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at .

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide + phenylephrine ophthalmic spray) for mydriasis, as well as the ongoing late-stage development of medications in the Optejet device for presbyopia and myopia progression (partnered with Bausch+Lomb). For more information, visit .

The Eyenovia Corporate Information slide deck may be found at .

Eyenovia Contact:

Eyenovia, Inc.

John Gandolfo

Chief Financial Officer

Eyenovia Investor Contact:

Eric Ribner

LifeSci Advisors, LLC



(646) 751-4363

Eyenovia Media Contact:

Eyenovia, Inc.

Norbert Lowe

Vice President, Commercial Operations





EN
07/08/2023

Underlying

EYENEyenovia Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eyenovia Inc

 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Provides Corporate Update and Reports Second Quarter 202...

Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results Successfully establishes cryptocurrency treasury reserve focused on the HYPE token and becomes the first publicly listed U.S. company to implement DeFi strategies on Hyperliquid blockchain Accumulates more than 1.5 million HYPE to date and establishes co-branded validator with Kinetiq Reiterates FDA registration of the Optejet User Filled Device (UFD) remains on track for September 2025 LAGUNA HILLS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD), the first publicly-...

August 13, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, Augu...

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025 Company to host an investor conference call and webcast at 4:30 pm ET NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or...

August 8, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYP...

Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy Increases total holdings to 1,535,772 HYPE Company to host investor webinar on Tuesday, July 29th at 2:00pm ET LAGUNA HILLS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced that it has acquired an additional 108,594 HYPE tokens, expanding its total holdings to 1,535,772 HYPE purchased at an average price of $36.14 per token. This latest purchase is in preparation of deploying HYPE into Kinetiq’s iHYPE (“Institutional HYPE”) po...

July 28, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evol...

Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025 LAGUNA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced that it will host a special corporate update event on Tuesday, July 29, 2025 at 2:00 PM ET with CIO Hyunsu Jung and CEO Michael Rowe, to discuss the Company's bold transformation from a digital ophthalmic tech company into the first publicly-listed U.S. firm focused on building a strategic treasury around HYP...

July 17, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings Increases total holdings to 1,427,178 HYPE LAGUNA HILLS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 120,726 HYPE tokens, expanding its total holdings to 1,427,178 HYPE purchased at an average price of $35.38 per token. “This latest acquisition...

July 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch